Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€91.20

€91.20

2.010%
1.8
2.010%
-
 
17:40 / Tradegate WKN: 907122 / Symbol: NVS / Name: Novartis / Stock / Pharmaceuticals / Large Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Novartis AG ADR Stock

There is an upward development for Novartis AG ADR compared to yesterday, with an increase of €1.80 (2.010%).
So far the community has only identified positive things for Novartis AG ADR stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".

Pros and Cons of Novartis AG ADR in the next few years

Pros
?
B****
?
C******** o* t** e**********
?
M***** P*******
Cons
?
S********** s********
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Novartis AG ADR vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Novartis AG ADR 2.010% 0.676% 0.224% -1.974% -1.974% 21.467% 29.565%
Roche Holding AG ADR 1.010% 0.872% 0.165% -19.062% -10.263% -17.988% -
Bayer AG ADR 5.560% -3.077% -1.563% -57.432% -26.744% -54.015% -58.278%
GSK plc ADR 0.000% -3.141% -5.612% 10.119% 10.119% -5.732% -16.384%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-04-15

Upon reviewing the financial statements of Novartis (NASDAQ: NVS), a prominent player in the pharmaceutical industry, the general impression suggests that the company maintains a solid financial standing. With substantial total assets, a strong revenue base, and a broad diversification through various investments, Novartis appears to be a robust organization in terms of financial health.

Cash Position: Novartis has maintained a considerable cash position in recent years, end of 2022 standing at $7.52B. A strong liquidity profile allows the company to invest in research and development or pursue mergers and acquisitions to drive future growth.

Increasing Revenue: The total revenue increased from $49.9B in 2020 to $52.9B in 2021 and further up to $58.2B in 2022. This growth suggests that the company is effectively generating business, increasing market share, and expanding its product portfolio.

Comments

Novartis AG (NYSE: NVS) is now covered by analysts at StockNews.com. They set a "strong-buy" rating on the stock.
Ratings data for NVS provided by MarketBeat
Show more

News

Novartis Ag (NVS) Q1 2024 Earnings Call Transcript: https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template-2023-01-12.jpg
Novartis Ag (NVS) Q1 2024 Earnings Call Transcript

Image source: The Motley Fool.

Novartis Ag (NYSE: NVS)Q1 2024 Earnings CallApr 23, 2024, 8:00 a.m. ET

Operator

Continue reading

Source Fool.com

2 High-Yield Dividend Stocks to Buy and Hold for 10 Years: https://g.foolcdn.com/editorial/images/772614/pharmacist-talking-to-patient.jpg
2 High-Yield Dividend Stocks to Buy and Hold for 10 Years

Great dividend stocks don't always have particularly high yields. Still, it's nice to see a solid income stock that boasts one that's higher than average. And if this company can reward its

1 Magnificent Dividend Stock to Buy and Hold: https://g.foolcdn.com/editorial/images/769890/patient-and-doctor-talking.jpg
1 Magnificent Dividend Stock to Buy and Hold

There are plenty of dividend stocks on the market. However, some raise their payouts irregularly, while others don't have businesses that look robust enough to support payout growth for a long time